Current status and future prospects of tumor-associated macrophages and PD-1/PD-L1 in gastric cancer immunotherapy
Gastric cancer(GC)is a common malignant tumor with a high incidence and elevated mortality rate.In recent years,PD-1/PD-L1 immune checkpoint inhibitors have rapidly become one of common treatments for GC due to their superior efficacy.Notably,recent studies have highlighted the critical role of tumor microenvironment in cancer progression.Among various cell types present in the tumor microenvironment,tumor-associated macrophages(TAMs)are the most abundant.These macrophages can express PD-1 and interact with PD-L1 on the surface of cancer cells.Therefore TAMs may influence the therapeutic effectiveness of PD-1/PD-L1 immune checkpoint inhibitors for GC.However,there are few current researches on this topic and the underlying mechanisms have remain elsuive.This review summarized the latest researches to provide more treatment options for GC patients.
Tumor-associated macrophagesProgrammed death protein-1Programmed death-ligand 1ImmunotherapyGastric Cancer
NETL
NSTL
万方数据
